Compare Mesoblast Limited (MESO) vs Modine Manufacturing Company (MOD) Price & Performance

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal and key support at $184. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 exceeding the $1.30 forecast. Recent corporate actions include the completion of a $946.4 million spin-off of its Performance Technologies unit with Gentherm, potentially reshaping its business focus toward thermal management solutions.

The outlook remains supported by strong analyst sentiment with a $331.25 consensus price target and 77% buy ratings, but risks include a high P/E ratio of 67.87 and a projected decline in net profit margin to 4.27% for 2026. The stock offers growth potential from its data center cooling expansion but faces execution risks post-spin-off and competitive pressures in the auto parts sector.